CY1107997T1 - Νεες μεθοδοι που χρησιμοποιουν αναστολεις της χολινεστepασης - Google Patents

Νεες μεθοδοι που χρησιμοποιουν αναστολεις της χολινεστepασης

Info

Publication number
CY1107997T1
CY1107997T1 CY20071100121T CY071100121T CY1107997T1 CY 1107997 T1 CY1107997 T1 CY 1107997T1 CY 20071100121 T CY20071100121 T CY 20071100121T CY 071100121 T CY071100121 T CY 071100121T CY 1107997 T1 CY1107997 T1 CY 1107997T1
Authority
CY
Cyprus
Prior art keywords
dementia
syndrome
prevention
treatment
novel methods
Prior art date
Application number
CY20071100121T
Other languages
English (en)
Inventor
Raymond Pratt
Original Assignee
Eisai R&D Management Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co., Ltd. filed Critical Eisai R&D Management Co., Ltd.
Publication of CY1107997T1 publication Critical patent/CY1107997T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Η παρούσα εφεύρεση περιγράφει νέες μεθόδους για τη θεραπεία και τη πρόληψη της άνοιας που προκαλείται από αγγειακές νόσους, της άνοιας που συνδέεται με τη νόσο του Parkinson, της άνοιας του Σώματος Lewy, της άνοιας ένεκα του AIDS, των ήπιων νοητικών βλαβών, των βλαβών της μνήμης που συνδέονται με την ηλικία, των νοητικών βλαβών και/ή της άνοιας που συνδέονται με νευρολογικές και/ή ψυχιατρικές παθήσεις, που συμπεριλαμβάνουν την επιληψία, τους εγκεφαλικούς όγκους, τις εγκεφαλικές βλάβες (αλλοιώσεις), τη σκλήρυνση κατά πλάκας, το σύνδρομο Down, το σύνδρομο Rett, τη προοδευτική υπερπυρηνική πάρεση, το σύνδρομο του μετωπικού λοβού, και τη σχιζοφρένια και των σχετικών ψυχιατρικών διαταραχών, των νοητικών βλαβών που προκαλούνται από τραυματική εγκεφαλική βλάβη, χειρουργική επέμβαση μοσχεύματος μετα-στεφανιαίας παράκαμψης (by-pass), ηλεκτροσπασμωδική θεραπεία με σοκ και χημειοθεραπεία, χορηγώντας μια θεραπευτικά αποτελεσματική ποσότητα τουλάχιστον μιας από τις ενώσεις του αναστολέα της χολινεστεράσης που περιγράφονται εδώ. Η παρούσα εφεύρεση περιγράφει επίσης νέες μεθόδους για τη θεραπεία και τη πρόληψη του παραληρήματος, του συνδρόμου Tourette, της μυασθένειας gravis, της διαταραχής της υπερενεργότητας με έλλειψης προσοχής, του αυτισμού, της δυσλεξίας, της μανίας, της κατάθλιψης, της απάθειας και της μυοπάθειας που συνδέεται με τον διαβήτη, χορηγώντας μια θεραπευτικά αποτελεσματική ποσότητα τουλάχιστον μιας από τις ενώσεις του αναστολέα της χολινεστεράσης που περιγράφονται εδώ. Η παρούσα εφεύρεση περιγράφει επίσης νέες μεθόδους για τη καθυστέρηση της έναρξης της νόσου του Alzheimer, ώστε να ενισχυθούν οι νοητικές λειτουργίες, για τη θεραπεία και τη πρόληψη της άπνοιας του ύπνου, για την
CY20071100121T 2000-03-03 2007-01-29 Νεες μεθοδοι που χρησιμοποιουν αναστολεις της χολινεστepασης CY1107997T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18674400P 2000-03-03 2000-03-03
US19761000P 2000-04-18 2000-04-18
US22078300P 2000-07-25 2000-07-25
US25922601P 2001-01-03 2001-01-03
EP01922272A EP1311272B1 (en) 2000-03-03 2001-03-05 Novel methods using cholinesterase inhibitors

Publications (1)

Publication Number Publication Date
CY1107997T1 true CY1107997T1 (el) 2013-09-04

Family

ID=27497683

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100121T CY1107997T1 (el) 2000-03-03 2007-01-29 Νεες μεθοδοι που χρησιμοποιουν αναστολεις της χολινεστepασης

Country Status (11)

Country Link
US (7) US20020035128A1 (el)
EP (5) EP2140868A1 (el)
JP (1) JP2003525903A (el)
AT (1) ATE345803T1 (el)
AU (1) AU2001249091A1 (el)
CY (1) CY1107997T1 (el)
DE (1) DE60124730T2 (el)
DK (1) DK1311272T3 (el)
ES (1) ES2275670T3 (el)
PT (1) PT1311272E (el)
WO (1) WO2001066114A1 (el)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2275670T3 (es) * 2000-03-03 2007-06-16 EISAI R&D MANAGEMENT CO., LTD. Metodos novedosos utilizando inhibidores de colinesterasa.
US20030153598A1 (en) * 2000-07-25 2003-08-14 Raymond Pratt Methods for treating Parkinson's disease with cholinesterase inhibitors
US20060183776A9 (en) * 2000-03-03 2006-08-17 Eisai Co., Ltd. Liquid dosage formulations of donepezil
CA2442717A1 (en) * 2001-03-15 2002-09-26 Saegis Pharmaceuticals, Inc. Methods for restoring cognitive function following systemic stress
JP2005502680A (ja) * 2001-08-30 2005-01-27 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 抗痙攣剤およびアセチルコリンエステラーゼ阻害剤による痴呆および記憶障害の処置
WO2003032914A2 (en) * 2001-10-17 2003-04-24 Eisai Co., Ltd. Methods for treating substance abuse with cholinesterase inhibitors
JPWO2003061658A1 (ja) * 2002-01-22 2005-05-19 エーザイ株式会社 インダノン誘導体を含有するシグマ受容体結合剤
US20030162770A1 (en) * 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
AU2003298514A1 (en) * 2002-05-17 2004-05-04 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
US20070053976A1 (en) * 2002-05-17 2007-03-08 Eisai R & D Management Co., Ltd. Novel combination of drugs as antidepressant
WO2004009026A2 (en) * 2002-07-22 2004-01-29 Duke University Cholinergic therapy for individuals with learning disabilities
US20040142970A1 (en) * 2002-11-01 2004-07-22 Kathryn Chung Treatment of hyperkinetic movement disorder with donepezil
WO2004075916A1 (en) * 2003-02-27 2004-09-10 Shirankai Kyoto University Faculty Of Medicine Alumni Association Inc. Pharmaceutical composition for treatment of drug dependence
RU2379303C2 (ru) 2003-04-24 2010-01-20 Инсайт Корпорейшн Производные азаспироалканов в качестве ингибиторов металлопротеаз
US9119846B2 (en) * 2003-04-29 2015-09-01 Neurim Pharmaceuticals (1991) Ltd. Method and composition for enhancing cognition in alzheimer's patients
IL155666A (en) * 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment
AU2004251596B2 (en) * 2003-05-23 2008-04-17 Cognition Pharmaceuticals Llc Methods for treating cognitive impairment and improving cognition
SI1638933T1 (sl) 2003-06-17 2008-10-31 Pfizer Derivati N-pirolidin-3-il-amida kot inhibitorji ponovnega privzema serotonina in noradrenalina
EP1666066A4 (en) * 2003-09-19 2007-03-28 Eisai R&D Man Co Ltd DRUG AGAINST THE DOWN SYNDROME
US20050232990A1 (en) * 2003-12-31 2005-10-20 Garth Boehm Donepezil formulations
US20050277129A1 (en) * 2004-01-22 2005-12-15 Genaissance Pharmaceuticals APOE genetic markers associated with age of onset of Alzheimer's disease
JP2007519733A (ja) * 2004-01-26 2007-07-19 コーテックス ファーマシューティカルズ インコーポレーティッド アンパカインにより誘導されるシナプス応答促通のコリンエステラーゼ阻害剤による増強方法
US20070129350A1 (en) * 2004-01-30 2007-06-07 Axonyx, Inc. Methods for treatment of diabetes
EP1732549A4 (en) * 2004-03-18 2009-11-11 Brigham & Womens Hospital METHOD FOR THE TREATMENT OF SYNUCLEINOPATHIES
US20050272722A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
CA2559221A1 (en) * 2004-03-18 2005-09-29 Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20050277629A1 (en) * 2004-03-18 2005-12-15 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies (Lansbury)
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
TW200533371A (en) * 2004-04-15 2005-10-16 Dainippon Pharmaceutical Co Medicament comprising a combination of an acetylcholinesterase inhibitor and a 5-substituted-3-oxadiazolyl-1,6-naphthyridin-2(1h)-one derivative
US20060135507A1 (en) * 2004-08-13 2006-06-22 Osamu Yokoyama Therapeutic agent for overactive bladder involved in aging
WO2006037047A2 (en) * 2004-09-27 2006-04-06 Bridge Pharma, Inc. The r-isomer of 2-{2-[n-(2-indanyl)-n-phenylamino]ethyl}piperidine and other dermal anesthetic agents
US7718674B2 (en) * 2004-09-27 2010-05-18 Bridge Pharma, Inc. Methods of relieving neuropathic pain with the S-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine
ATE511843T1 (de) * 2005-04-04 2011-06-15 Eisai R&D Man Co Ltd Dihydropyridin-verbindungen für neurodegenerative erkrankungen und demenz
GB0605544D0 (en) * 2006-03-20 2006-04-26 Univ Nottingham Genetic Markers For Alzheimer Disease
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
US7910108B2 (en) * 2006-06-05 2011-03-22 Incyte Corporation Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
CA2655809C (en) * 2006-07-21 2013-10-01 Bridge Pharma, Inc. Dermal anesthetic compounds
US8012994B1 (en) 2006-09-22 2011-09-06 Sevastyanov Victor V Method for the treatment of sensorineural hearing loss with donepezil hydrochloride (ARICEPT®)
US20100048628A1 (en) * 2006-12-01 2010-02-25 Sumiyo Nishi Method for suppressing discoloration over time of adhesive preparation containing donepezil
RU2452474C2 (ru) * 2006-12-01 2012-06-10 Нитто Денко Корпорейшн Стабилизированная адгезивная композиция, содержащая донепезил
JP2010520154A (ja) * 2007-03-05 2010-06-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 神経変性疾患のためのａｍｐａレセプターアンタゴニストおよびｎｍｄａレセプターアンタゴニスト
EP2148673A1 (en) * 2007-04-26 2010-02-03 Eisai R&D Management Co., Ltd. Cinnamide compounds for dementia
CA2685860A1 (en) * 2007-05-10 2008-11-20 Amr Technology, Inc. Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
EP2211911A4 (en) * 2007-10-31 2012-11-14 Alseres Pharmaceuticals Inc METHOD FOR DIAGNOSIS AND MONITORING OF THE TREATMENT OF LEWY BODILY DAMAGE BY EVALUATING THE DOPAMIN TRANSPORTER MIRROR
US20090156561A1 (en) * 2007-12-13 2009-06-18 Seed John C Use of Cholinesterase Inhibitors In Smoking Cessation
US8232402B2 (en) * 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
WO2009128057A2 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
WO2009128058A1 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
US20090291127A1 (en) * 2008-05-21 2009-11-26 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
EP2279739B2 (en) * 2008-05-30 2018-02-28 Nitto Denko Corporation Donepezil-containing patch preparation and packaging thereof
RU2483729C2 (ru) * 2008-05-30 2013-06-10 Нитто Денко Корпорейшн Чрескожно абсорбируемый препарат
BRPI0917862A2 (pt) * 2008-09-30 2015-11-24 Teikoku Pharma Usa Inc composições transdérmicas de donepezil com distribuição prolongada e métodos para usar as mesmas
WO2010057006A1 (en) * 2008-11-13 2010-05-20 Link Medicine Corporation Azaquinolinone derivatives and uses thereof
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
AU2010236734B2 (en) * 2009-04-13 2015-06-11 Theravance Biopharma R&D Ip, Llc 5-HT4 receptor agonist compounds for treatment of cognitive disorders
US20100178307A1 (en) * 2010-01-13 2010-07-15 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
CN102905532A (zh) 2010-02-09 2013-01-30 约翰斯.霍普金斯大学 用于改善认知功能的方法和组合物
EP2366378A1 (en) 2010-03-01 2011-09-21 Dexcel Pharma Technologies Ltd. Sustained-release donepezil formulations
WO2011127235A1 (en) 2010-04-07 2011-10-13 Eisai Inc. Combination therapy for the treatment of dementia
GR1007368B (el) 2010-05-27 2011-08-02 Alapis Α.Β.Ε.Ε., Ποσιμα φαρμακευτικα διαλυματα για τη θεραπεια των συμπτωματων της ανοιας
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
EP2642998B1 (en) 2010-11-24 2020-09-16 The Trustees of Columbia University in the City of New York A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease
US20120225922A1 (en) 2011-03-04 2012-09-06 Qr Pharma Effective Amounts of (3aR)-1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo [2,3-b]indol-5-yl Phenylcarbamate and Methods of Treating or Preventing Neurodegeneration
WO2013109543A1 (en) * 2012-01-20 2013-07-25 The Board Of Trustees Of The Leland Stanford Junior University Small molecule cmklr1 antagonists in demyelinating disease
WO2013166037A1 (en) 2012-05-01 2013-11-07 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of eye disorders
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
WO2014151936A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles, their preparation and use
US9938291B2 (en) 2013-03-14 2018-04-10 The Trustess Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
EP2968304B1 (en) 2013-03-14 2018-10-10 The Trustees of Columbia University in the City of New York 4-phenylpiperidines, their preparation and use
WO2014152018A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York Octahydrocyclopentapyrroles, their preparation and use
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
WO2014144801A1 (en) 2013-03-15 2014-09-18 Agenebio Inc. Methods and compositions for improving cognitive function
US9359315B2 (en) 2013-09-10 2016-06-07 Arrien Pharmaceuticals Llc Substituted 2,3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis
SG11201608943VA (en) 2014-04-30 2016-11-29 Univ Columbia Substituted 4-phenylpiperidines, their preparaiton and use
TWI698436B (zh) 2014-12-30 2020-07-11 美商佛瑪治療公司 作為泛素特異性蛋白酶７抑制劑之吡咯并及吡唑并嘧啶
MA41291A (fr) 2014-12-30 2017-11-07 Forma Therapeutics Inc Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
WO2016126935A1 (en) 2015-02-05 2016-08-11 Forma Therapeutics, Inc. Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors
US9840491B2 (en) 2015-02-05 2017-12-12 Forma Therapeutics, Inc. Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors
US9932351B2 (en) 2015-02-05 2018-04-03 Forma Therapeutics, Inc. Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors
EA034167B8 (ru) 2015-05-22 2021-04-27 Эйджинбайо, Инк. Фармацевтические композиции леветирацетама пролонгированного высвобождения
CN107921024B (zh) * 2015-08-14 2021-09-10 Qr制药公司 治疗或预防急性脑损伤或神经损伤的方法
US20180338950A1 (en) 2017-05-24 2018-11-29 Qr Pharma, Inc. Prevention or Treatment of Disease States Due to Metal Dis-Homeostasis Via Administration of Posiphen to Healthy or Sick Humans
JP2021501210A (ja) 2017-10-30 2021-01-14 モントリオール ハート インスティテュート 血漿コレステロールの上昇を処置する方法
EP3999051A4 (en) * 2019-07-16 2023-08-02 Rush University Medical Center USE OF A COMPOSITION CONTAINING BENZOATE FOR TREATING NEURODEGENERATIVE DISORDERS

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL74497A (en) * 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
US4826843A (en) * 1985-07-08 1989-05-02 Bristol-Myers Cerebral function enhancing diazinylpiperidine derivatives
FI95572C (fi) 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
JP2777159B2 (ja) * 1988-12-22 1998-07-16 エーザイ株式会社 環状アミン誘導体を含有する医薬
JP3075566B2 (ja) 1990-05-15 2000-08-14 エーザイ株式会社 光学活性インダノン誘導体
JP2965675B2 (ja) 1990-11-21 1999-10-18 エーザイ株式会社 （―）―１―ベンジル―４―〔（５，６―ジメトキシ―１―インダノン）―２―イル〕メチルピペリジンの製造方法
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
CA2113115A1 (en) * 1991-07-29 1993-02-18 Vlad E. Gregor Quinazoline derivatives as acetylcholinesterase inhibitors
SE9103752D0 (sv) * 1991-12-18 1991-12-18 Astra Ab New compounds
AU1153097A (en) 1996-06-07 1998-01-05 Eisai Co. Ltd. Stable polymorphs of donepezil (1-benzyl-4-{(5,6-dimethoxy-1-indanon)-2-yl}methylpiperidine ) hydrochloride and process for production
CA2252806C (en) 1996-06-07 2005-11-22 Eisai Co., Ltd. Polymorphs of donepezil hydrochloride and process for production
TW513409B (en) 1996-06-07 2002-12-11 Eisai Co Ltd Polymorphs of donepezil hydrochloride
AU4078997A (en) * 1996-08-22 1998-03-06 New York University Cholinesterase inhibitors for treatment of parkinson's disease
WO1998039000A1 (en) 1997-03-03 1998-09-11 Eisai Co., Ltd. Use of cholinesterase inhibitors to treat disorders of attention
AU9454098A (en) * 1997-09-24 1999-04-12 Nova Molecular, Inc. Methods for increasing apoe levels for the treatment of neurodegenerative disease
DE69822218T2 (de) 1997-12-05 2005-02-03 Eisai Co., Ltd. Donepezil polykristalle und verfharen zu ihrer herstellung
ATE292116T1 (de) 1998-01-16 2005-04-15 Eisai Co Ltd Verfahren zur herstellung von donepezilderivaten
US6193993B1 (en) 1998-03-03 2001-02-27 Eisai Co., Ltd. Suppository containing an antidementia medicament
KR100746753B1 (ko) 1998-08-28 2007-08-06 에자이 알앤드디 매니지먼트 가부시키가이샤 고미 등을 경감한 의약조성물
IT1304904B1 (it) 1998-09-11 2001-04-05 Eisai Co Ltd Derivati anticolinesterasici per il trattamento delle sindromidolorose funzionali e/o organiche
US6372760B1 (en) 1999-03-31 2002-04-16 Eisai Co., Ltd. Stabilized composition comprising antidementia medicament
US20060183776A9 (en) * 2000-03-03 2006-08-17 Eisai Co., Ltd. Liquid dosage formulations of donepezil
ES2275670T3 (es) * 2000-03-03 2007-06-16 EISAI R&D MANAGEMENT CO., LTD. Metodos novedosos utilizando inhibidores de colinesterasa.
US20030153598A1 (en) * 2000-07-25 2003-08-14 Raymond Pratt Methods for treating Parkinson's disease with cholinesterase inhibitors
AU2001239052A1 (en) 2000-03-06 2001-09-17 Immune Network Ltd. Compositions for prevention and treatment of dementia
US20010036949A1 (en) 2000-05-09 2001-11-01 Coe Jotham Wadsworth Pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal
WO2003024450A1 (en) 2001-09-20 2003-03-27 Eisai Co., Ltd. Methods for treating prion diseases
WO2003024456A1 (en) 2001-09-20 2003-03-27 Eisai Co., Ltd. Methods for treating and preventing migraines
WO2003032914A2 (en) 2001-10-17 2003-04-24 Eisai Co., Ltd. Methods for treating substance abuse with cholinesterase inhibitors
GB2405336A (en) 2002-05-01 2005-03-02 Eisai Co Ltd Cholinesterase inhibitors to prevent injuries caused by chemicals
AU2003298514A1 (en) 2002-05-17 2004-05-04 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
US20040142970A1 (en) * 2002-11-01 2004-07-22 Kathryn Chung Treatment of hyperkinetic movement disorder with donepezil

Also Published As

Publication number Publication date
EP1311272A4 (en) 2003-05-21
ATE345803T1 (de) 2006-12-15
AU2001249091A1 (en) 2001-09-17
EP1311272A1 (en) 2003-05-21
US20020035128A1 (en) 2002-03-21
WO2001066114A1 (en) 2001-09-13
US6458807B1 (en) 2002-10-01
DE60124730D1 (de) 2007-01-04
DE60124730T2 (de) 2007-10-04
EP2138177A1 (en) 2009-12-30
PT1311272E (pt) 2007-02-28
US6689795B2 (en) 2004-02-10
US7563808B2 (en) 2009-07-21
US6576646B1 (en) 2003-06-10
US20040122051A1 (en) 2004-06-24
JP2003525903A (ja) 2003-09-02
EP2133078A1 (en) 2009-12-16
US20050250812A1 (en) 2005-11-10
US20020035129A1 (en) 2002-03-21
ES2275670T3 (es) 2007-06-16
EP2140868A1 (en) 2010-01-06
DK1311272T3 (da) 2007-02-26
US20030040532A1 (en) 2003-02-27
US6482838B2 (en) 2002-11-19
EP2130538A1 (en) 2009-12-09
US20020040038A1 (en) 2002-04-04
EP1311272B1 (en) 2006-11-22

Similar Documents

Publication Publication Date Title
CY1107997T1 (el) Νεες μεθοδοι που χρησιμοποιουν αναστολεις της χολινεστepασης
AU2001273574A1 (en) Substituted 5-alkynyl pyrimidines having neurotrophic activity
RU2405774C2 (ru) Гетероциклические ингибиторы аспартилпротеазы
WO2001078711A3 (en) Pde-v inhibitors for treatment of parkinson's disease
RU98114683A (ru) Производные 5-н-тиазол[3,2-a]пиримидина
WO2003051315A3 (en) Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5
UA27911C2 (uk) Засіб для лікування або запобігання фізіологічних розладів, які викликані надлишком тахікініну
TR199902291T2 (xx) �kame edilmi� 4-Arilmetilen-2-imino-2, 3-dihidrotiazoller
ATE253918T1 (de) Verwendung von hymenialdisin und dessen derivaten zur herstellung therapeutischer mittel
HK1050894A1 (en) Aryl fused azapolycyclic compounds
DE60336890D1 (de) Kondensierte pyridazinderivat-verbindungen und die verbindungen als wirkstoff enthaltende arzneimittel
CA2339008A1 (en) Methods for increasing cytidine levels in vivo and treating cytidine-dependent human diseases
TW200505907A (en) Piperidine-benzenesulfonamide derivatives
UA66825C2 (uk) Азаполіциклічні сполуки, конденсовані з арилом, фармацевтична композиція, спосіб лікування та спосіб зниження нікотинової залежності
WO1998020864A3 (en) Use of selected non-steroidal antiinflammatory compounds for the prevention and the treatment of neurodegenerative diseases
GC0000375A (en) Benzodiazepine derivatives as gaba a receptor modulators
PT912184E (pt) Utilizacao de um derivado de k-252a para o tratamento de doencas do sietma nervoso central ou periferico e sobre-producao de citoquina
WO2001098279A3 (en) Bis-arylsulfones
RU2003128982A (ru) Карбаматы для предотвращения или лечения нейродегенеративных нарушений
BR9509353A (pt) Utilzação de diazepino-indolas as respectivas diazepino- indolas e medicamen to
YU12003A (sh) Novi derivati aminocikloheksana
BG103252A (en) The use of benzopyranols for the treatment of neurological disorders
AR022083A1 (es) Derivados de piperidina
AU2002227895A1 (en) Sulphonamides for the treatment of central nervous system diseases
MY121206A (en) Aminobenzamide compounds for the treatment of neurodegenerative disorders